Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca's Fluenz Tetra gets EC approval for the prevention of seasonal influenza in children


Thursday, 5 Dec 2013 07:00pm EST 

AstraZeneca PLC:Says the European Commission (EC) has granted Marketing Authorisation to FluenzTM Tetra.Says Fluenz Tetra is a nasally administered four-strain live attenuated influenza vaccine for the prevention of influenza in children and adolescents from 24 months up to 18 years of age.Says the EC approval makes Fluenz Tetra the first and only intra-nasal four-strain influenza vaccine available in Europe. 

Company Quote

4469.5
4.5 +0.10%
27 Feb 2015